Market Exclusive

Amedisys Inc (NASDAQ:AMED) gets upgraded to Buy by Benchmark with a price target of $125.00

Analyst Ratings For Amedisys Inc (NASDAQ:AMED)

Today, Amedisys Inc (NASDAQ:AMED) stock received an upgrade by Benchmark from Hold to Buy with a price target of $125.00.

There are 8 Buy Ratings, 5 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Amedisys Inc (NASDAQ:AMED) is Buy with a consensus target price of $104.25 per share, a potential 9.92% downside.

Some recent analyst ratings include


About Amedisys Inc (NASDAQ:AMED)
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Recent Trading Activity for Amedisys Inc (NASDAQ:AMED)
Shares of Amedisys Inc closed the previous trading session at 115,88 up +14,99 14,86 % with 789256 shares trading hands.

Exit mobile version